2023
Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study—December 20, 2020—June 20, 2022
Wang R, Gottlieb M, Montoy J, Rodriguez R, Yu H, Spatz E, Chandler C, Elmore J, Hannikainen P, Chang A, Hill M, Huebinger R, Idris A, Koo K, Li S, McDonald S, Nichol G, O’Laughlin K, Plumb I, Santangelo M, Saydah S, Stephens K, Venkatesh A, Weinstein R, Weinstein R, Gottlieb M, Santangelo M, Koo K, Derden A, Gottlieb M, Gatling K, Guzman D, Yang G, Kaadan M, Hassaballa M, Jerger R, Ahmed Z, Choi M, Venkatesh A, Spatz E, Lin Z, Li S, Yu H, Liu M, Venkatesh A, Spatz E, Ulrich A, Kinsman J, Dorney J, Pierce S, Puente X, Nichol G, Stephens K, Anderson J, Morse D, Adams K, Maat Z, Stober T, O’Laughlin K, Gentile N, Geyer R, Willis M, Ruiz L, Malone K, Park J, Rising K, Kean E, Kelly M, Schaeffer K, Hannikainen P, Shughart L, Shughart H, Renzi N, Amadio G, Grau D, Watts P, Cheng D, Miao J, Shutty C, Charlton A, Hill M, Site R, Chavez S, Kane A, Nikonowicz P, Idris A, McDonald S, Gallegos D, Martin R, Elmore J, Wisk L, L’Hommedieu M, Chandler C, Eguchi M, Roldan K, Villegas N, Moreno R, Rodriguez R, Wang R, Montoy J, Kemball R, Chan V, Chavez C, Wong A, Arreguin M, Plumb I, Hall A, Saydah S, Briggs-Hagen M. Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study—December 20, 2020—June 20, 2022. Open Forum Infectious Diseases 2023, 10: ofad275. PMID: 37426947, PMCID: PMC10327880, DOI: 10.1093/ofid/ofad275.Peer-Reviewed Original ResearchLoss of smellAcute symptomsSARS-CoV-2SARS-CoV-2 positive participantsFrequency of acute symptomsPrevalence of acute symptomsShortness of breathLoss of tasteChest painClinical presentationReport symptomsRespiratory virusesCohort studySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 variantsSore throatRespiratory syndrome coronavirus 2Runny noseSyndrome coronavirus 2Coronavirus disease 2019ParticipantsSymptomsCoronavirus 2Omicron
2022
Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis
Doria D, Santin A, Tuszynski J, Scheim D, Aminpour M. Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis. BioMedInformatics 2022, 2: 553-564. DOI: 10.3390/biomedinformatics2040035.Peer-Reviewed Original ResearchSpike 1 proteinCholinergic anti-inflammatory pathwayAnti-inflammatory pathwayGenetic alterationsParasympathetic nervous systemOmicron infectionCOVID-19 variantsAutonomic dysregulationClinical dataPreclinical resultsNatural immunitySevere formAnimal modelsNervous systemΑ7nAChRTherapeutic antibodiesAttenuation of virulenceCOVID-19InfectionPrevious variantsAttenuated natureOmicronDominant strainAlterationsHumansEffectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, Almiron M, de Oliveira RD, Cummings DAT, Dean NE, Andrews JR, Ko AI, Croda J. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications 2022, 13: 5536. PMID: 36202800, PMCID: PMC9537178, DOI: 10.1038/s41467-022-33169-0.Peer-Reviewed Original ResearchOmicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications 2022, 13: 3250. PMID: 35668119, PMCID: PMC9169595, DOI: 10.1038/s41467-022-30878-4.Peer-Reviewed Original ResearchConceptsHeterologous boosterSARS-CoV-2Antibody responseMRNA vaccinesMRNA vaccinationDelta variantOmicron variantType of vaccinationStrong antibody responseMRNA vaccine candidatesVaccine candidatesNeutralization potencyImmune evasionSARS-CoV.Two weeksComparable titersVaccinationVaccineTiters 10MiceOmicronWeeksWA-1LNP-mRNABoosterSARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022
Baker J, Nakayama J, O’Hegarty M, McGowan A, Teran R, Bart S, Mosack K, Roberts N, Campos B, Paegle A, McGee J, Herrera R, English K, Barrios C, Davis A, Roloff C, Sosa L, Brockmeyer J, Page L, Bauer A, Weiner J, Khubbar M, Bhattacharyya S, Kirking H, Tate J. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 341-346. PMID: 35238860, PMCID: PMC8893332, DOI: 10.15585/mmwr.mm7109e1.Peer-Reviewed Original ResearchConceptsHousehold contactsIndex patientCOVID-19 primary seriesSARS-CoV-2Prevention strategiesCOVID-19 booster doseEffectiveness of prevention strategiesBooster dosePrimary seriesOmicron infectionPatientsOmicron transmissionHousehold transmissionVariant transmissionInfected personsHousehold settingsCOVID-19Cases of COVID-19InfectionOmicron
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply